Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H2 2017

  • KMI-73262
  • Jul 2017
  • 43 pages
  • Healthcare
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).

The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Dermatology, Immunology, Gastrointestinal, Central Nervous System, Infectious Disease, Oncology, Ophthalmology and Respiratory which include indications Atopic Dermatitis, Rheumatoid Arthritis, Actinic (Solar) Keratosis, Acute Lung Injury, Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Genital Warts (Condylomata Acuminata), Inflammation, Inflammatory Bowel Disease, Melanoma, Multiple Sclerosis, Posterior Uveitis, Psoriasis, Soft Tissue Sarcoma and Warts.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
Alvotech Iceland
Eli Lilly and Company
Eyevensys SAS
G&E Herbal Biotechnology Co Ltd
GlaxoSmithKline Plc
Inflamalps SA
Polaris Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3232094 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNF-R1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNF-PEG 20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
May 09, 2017: Eyevensys Announces the First-in-Human Treatment with its Groundbreaking EyeCET ElectroTransfection Technology for Eye Diseases
Apr 20, 2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
Apr 11, 2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
May 31, 2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Feb 18, 2016: Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

   Global Healthcare IT Consulting Market By Type (Strategy, Project Management, Integration, Migration, Security, Risk assessment, Analytics, BPM, Regulatory), End User (Hospitals, IDN, ACC, Home, Payer, Public, Private) and Region (North America, Asia Pacific, Europe, Latin America, Rest of the World) Market Size, Status and Forecast to 2025

   Global Life Science Analytics Market By Type (Descriptive, Prescriptive), Application (Marketing, Compliance, R&D, SCM), Component (Software, Service), Delivery (on premise, cloud) and End user (Pharmaceutical, Biotechnology, Medical Device, CRO), and Region (North America, Asia Pacific, Europe, Latin America, Rest of the World) Market Size, Status and Forecast to 2025

   Global ECG Cable and ECG Lead wires Market By Material (Thermoplastic Elastomer, TPU), Usability (Reusable, Disposable), ECG Lead wires by Machine Type (3 lead, 5 lead), Patient Care Setting (Long term care facilities, Home care) and Regional Market Size, Status and Forecast to 2025

   Global Defibrillators Market By Product (Implantable Cardioverter Defibrillator (Transvenous ICD, Single & Dual Chamber, CRT-D, S-ICD) and External (Manual, AED, Wearable)), End User (Hospital, Prehospital, Public Access, Home) and Regional Market Size, Status and Forecast to 2025

   Global Cardiac Marker Testing Market By Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemi-luminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) and Regional Market Size, Status and Forecast to 2025

   Global Atrial Fibrillation Surgery Market By Procedure (Catheter Ablation, Surgical Ablation/Maze), Product (Catheter Ablation, Surgical Ablation), and Geography (Canada, China, France, Germany, India, Japan, U.S., U.K.) and Regional Market Size, Status and Forecast to 2025

   Global Anatomic Pathology Market By Product & Service (Instruments (Tissue Processing Systems, Microtome), Consumables (Reagent & Antibodies), Histopathology, Cytopathology), Application (Disease Diagnosis, Drug Discovery & Development) and Regional Market Size, Status and Forecast to 2025

   Global Healthcare Mobility Solutions Market By Products & Services (Mobile Devices, Mobile Apps, Enterprise Platforms), Application (Patient Care, Operations, Workforce Management), End User (Payers, Providers, Patients) and Regional Market Size, Status and Forecast to 2025

   Global Pharmacovigilance and Drug Safety Software Market By Source (Whole Grain Products, Fruits & Vegetables, Others), Product (Soluble Dietary Fibers, Insoluble Dietary Fibers), Application (Food, Beverages, Pharmaceuticals, Others) and Regional Market Size, Status and Forecast to 2025

   Global Preimplantation Genetic Testing Market By Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) and Regional Market Size, Status and Forecast to 2025

Purchase this Market Research Report



Contact Us


Mannan
Mannan Shaikh
Head-Sales
mansing
Mansingh Surve
Manager-Sales
Diksha
Diksha Singh Rathore
Team Lead-Sales
view